Exploratory analysis of factors associated with hyperprogression in advanced non-small cell lung cancer (NSCLC) treated with PD1/PDL1 inhibitors

Autor: Philip Ryan, M. Decatris, Ingrid Du Rand, Aled Phillips, Caitlin Bowden, Sherouk El-Batrawy, J. Thomas, Mark Hayes

Publikováno v: Journal of Clinical Oncology. 38:e21634-e21634

e21634 Background: Hyperprogressive disease(HPD) is a recently recognized type of accelerated tumor progression with immune checkpoint inhibitor(ICI) therapy. A recent meta-analysis identified serum lactate dehydrogenase(LDH) above upper limit of nor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cdb3e4a860748eb738b9520d1058cad4
https://doi.org/10.1200/jco.2020.38.15_suppl.e21634

P2.17-07 Concurrent Chemoradiotherapy (ConCRT) using Cisplatin-Vinorelbine in Locally Advanced (LA) Non-Small Cell Lung Cancer (NSCLC)

Autor: G. Orphanos, I. Porfiridis, N. Katodritis, I. Constantinou, H. Charalambous, F. Kyriacou, M. Decatris, D. Vomvas

Publikováno v: Journal of Thoracic Oncology. 13:S854

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::714e7da71c7e243777999bf3447302f1
https://doi.org/10.1016/j.jtho.2018.08.1533

Programmed death-ligand 1 (PD-L1) expression and testing experience in a cohort of advanced non-small cell lung cancer (NSCLC) patients

Autor: M. Decatris, K. Birchall, Philip Ryan, P. Taniere, J. Thomas, Mark Hayes, I. Du Rand, Aled Phillips, N. Reed, K. Gaikwad, V. Bhalla

Publikováno v: Lung Cancer. 115:S42

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25fd0b8495c1424d1f59bc79f98b3707
https://doi.org/10.1016/s0169-5002(18)30126-0

Adjuvant therapy in primary GIST: state-of-the-art

Autor: A. Le Cesne, Jaap Verweij, Heikki Joensuu, Paris Kosmidis, Peter Reichardt, J.-Y. Blay, Thomas Brodowicz, Mikael Eriksson, Marcus Schlemmer, M. Decatris, Hans Gelderblom, Antonio López Pousa, Ioannis Boukovinas, Javier Martin Broto, Paolo G. Casali

Publikováno v: Annals of Oncology, 23(11), 2776-2781
Annals of Oncology, 23(11), 2776-2781. Elsevier Ltd.
ANNALS OF ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

The management of primary gastrointestinal stromal tumours (GISTs) has evolved with the introduction of adjuvant therapy. Recently reported results of the SSG XVIII/AIO trial by the Scandinavian Sarcoma Group (SSG) and the German Working Group on Med

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1a639631842608d2cf68e30e85c4862
https://pubmed.ncbi.nlm.nih.gov/22831984

Pegamotecan (EZ-246), a novel PEGylated camptothecin conjugate, for treatment of adenocarcinomas of the stomach and gastroesophageal (GE) junction: Preliminary results of a single-agent phase 2 study

Autor: James C. Yao, L. C. Scott, M. Decatris, Stephen Falk, T. R.J. Evans, A. I. Benson, Jaffer A. Ajani, Mary F. Mulcahy, M. Rudoltz, Anne L. Thomas

Publikováno v: Journal of Clinical Oncology. 22:4030-4030

4030 Background: The results of a phase 1 study of pegamotecan have been published.1 This phase 2 study was designed to evaluate the activity of pegamotecan in advanced and metastatic adenocarcinomas of the stomach and GE junction. Methods: This mult

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8043c81fa73b7b93c4bb83964685e6b1
https://doi.org/10.1200/jco.2004.22.90140.4030